PDL BioPharma, Inc. (NASDAQ:PDLI)’s interesting series of developments are underway around the US stock market these days. Now trading with a market value of 378.16M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.PDL BioPharma, Inc. (NASDAQ:PDLI) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For PDLI, the company currently has 405.08 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 1.1 billion in total assets, balanced by 257.29 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
PDL BioPharma, Inc. (PDLI) saw -14.92 million in free cash flow last quarter, representing a quarterly net change in cash of -122.19 million. Perhaps most importantly where cash movements are concerned, the company saw about -13.52 million in net operating cash flow.PDL BioPharma, Inc. (NASDAQ:PDLI) Revenue Growth Potential
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 38.52 million in total revenues. That represents a quarterly year/year change in revenues of -0.15 in sequential terms, the PDLI saw sales decline by -0.43.
But what about the bottom line? After all, that’s what really matters in the end. PDL BioPharma, Inc. (PDLI) is intriguing when broken down to its core data. The cost of selling goods last quarter was 16.86 million, yielding a gross basic income of 21.66 million. For shareholders, given the total diluted outstanding shares of 152.58 million, this means overall earnings per share of 0.01.Is PDL BioPharma, Inc. (NASDAQ:PDLI) Valuation Attractive
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 0.23 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 16.93. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on PDL BioPharma, Inc..